PIMASERTIB AND SEROUS RETINAL DETACHMENTS.

Abstract

PURPOSE:

To report a case of multifocal serous retinal detachments associated with pimasertib.

METHODS:

The authors report a 26-year-old patient who developed bilateral multifocal serous retinal detachments appearing 2 days after starting pimasertib (as part of a clinical trial investigating its use in low-grade metastatic ovarian cancer) and rapidly resolving 3 days after stopping it.

CONCLUSION:

The mechanism of MEK inhibitor induced visual toxicity remains unclear. The pathophysiology of multifocal serous retinal detachments as a complication of pimasertib is still poorly understood.

• Authors: Alaa AlAli, Ahmad Bushehri, Jonathan C Park, Hatem Krema, Wai-Ching Lam
• Journal: Retinal cases & brief reports (Retin Cases Brief Rep) Vol. 10 Issue 2 Pg. 191-6 ( 2016) ISSN: 1937-1578 [Electronic] United States
• PMID: 26444523 (Publication Type: Case Reports, Journal Article)

Chemical References

• N-(2,3-dihydroxypropyl)-1-((2-fluoro-4-iodophenyl)amino)isonicotinamide
• Protein Kinase Inhibitors
• Niacinamide

Topics

• Administration, Oral
• Adult
• Dose-Response Relationship, Drug
• Female
• Fluorescein Angiography
• Follow-Up Studies
• Fundus Oculi
• Humans
• Niacinamide (administration & dosage, adverse effects, analogs & derivatives)
• Ovarian Neoplasms (drug therapy, secondary)
• Protein Kinase Inhibitors
• Retina (drug effects, pathology)
• Retinal Detachment (chemically induced, diagnosis)
• Tomography, Optical Coherence
• Visual Acuity